Aldehyde Dehydrogenase (ALDH) Activity Resolves Neuroblastoma (NB) Cells and Hematopoietic Stem and Progenitor Cells (HPC) in Graft Material: Potential Method for Clinical Purging.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2869-2869
Author(s):  
Sandra J. Foster ◽  
Lisa Winstead ◽  
Timothy A. Driscoll ◽  
Andrew E. Balber

Abstract High dose, myeloablative chemotherapy followed by autologous HPC transplantation is used clinically to treat NB in children. The presence of NB cells in transplant material adversely affects outcome. Grafts have been purged by using monoclonal antibodies to select CD34+ HPC for transplantation or to remove tumor cells expressing NB surface antigens from graft material. We are exploring the feasibility of purging NB autografts by flow sorting HPC and NB cells based on differential expression of ALDH. Cell populations with high levels of ALDH activity and low side scatter (ALDHbrSSClo cells) can be identified in mobilized peripheral blood (PBSC), bone marrow (BM), and umbilical cord blood using the ALDEFLUOR™ [StemCo Biomedical, Inc.] method for flow cytometric measurement of cellular ALDH activity. ALDHbrSSClo cells isolated by flow sorting are highly enriched for HPC activity. We report here that none of three established NB cell lines (SK-N-SH, SK-N-BE(2), and IMR-32) express detectable ALDH activity in the ALDEFLUOR™ assay. Furthermore, when any of these NB lines was labeled with the stable, red fluorescent intracellular marker SNARF™ [Molecular Probes, Inc.] and then mixed with BM or PBSC, NB were readily resolved from the green fluorescent ALDHbrSSClo cells. In mixtures containing equal numbers of tumor cells and PBSC or BM cells 0–6 events were detected in the ALDHbrSSClo region out of a total of 3-10 x 105 events in the SSC vs. FSC gate. Even when mixtures containing 9 tumor cells to 1 leukocyte were used, fewer than 21 SNARF-labeled NB were detected in the ALDHbrSSClo region out of a total of 2-9 x 105events in the SSC vs. FSC gate. Additional studies were done by sorting mixtures of SNARF-labeled NB cells and PBSC or BM and measuring tumor burden post-sort. In a representative study, pre-sort NB content of 30% was reduced to 0.04% when care was taken to eliminate NB-HPC doublets by using pulse width discrimination; without this precaution, NB contamination in the sorted cells was 1.3%. RNA was prepared from pre- and post-sorted cells, and real time PCR analysis was performed using probes to NB gene products tyrosine hydroxylase, GD2 synthase and PRAME. PCR signals were readily detected in the starting sample and were reduced by >1000-fold in the sorted ALDHbrSSClo cells. To extend these findings with NB cell lines to clinical material, a bone marrow sample was obtained from a NB patient following appropriate institutional consent procedures and was analyzed by multiparameter flow analysis using ALDEFLUOR™ and a monoclonal antibody to GD2 synthase, an antigen strongly expressed by NB cells. Approximately 60% of the cells in this BM sample expressed GD2 synthase, but only 0.03% of the NB cells were detected among ALDHbrSSClo events. RNA was prepared from 100,000 flow-sorted ALDHbrSSClo cells, and real-time PCR analysis was performed. NB gene products were readily detected in the donor BMs, but no signal was detected in the sorted cell preparations. The NB burden in the flow-sorted ALDHbrSSClo population was reduced >100-fold compared to the unpurged, heavily contaminated BM. We are extending this analysis to maximize purging obtainable with clinical material. As ALDEFLUOR™ does not impair any tested functional characteristics of HPC, flow sorting based ALDH activity may provide a new method to purge autografts of NB cells for clinical transplantation.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4547-4547
Author(s):  
Huanling Zhu ◽  
Ting Liu ◽  
Yongqian Jia

Abstract Objective To establish an imatinib resistance cell line and to study its resistant principia. Methods K562 cells were cultured in imatinib at gradually increased concentrations to generate their resistance cell line. Clone imatinib resistance cell lines by limited dilution culture. MTT assay, real time PCR and Semi-quantity PCR, flow cytometry and HPLC were used to clarify the possible mechanisms of the resistance. Results Imatinib resistance cell line K562R was successfully induced by continuous culture in the presence of gradually increasing doses of imatinib up to 5μmol/L. K562R cells were maintained in the media containing 5μmol/L imatinib. Proliferation data showed that cell growth of K562R was not inhibited in 5 μmol/L imatinib, whereas the parental sensitive cell was significantly inhibited by up to 2μM imatinib. The IC50 of K562R was about 7.5μmol/L which was ten times higher than that of the parental cell. HPLC revealed that the intracellular imatinib concentration of K562R was strikingly lower than that of the parental cells (up to 27.8-fold). MDR1 were not detected in mRNA (by RT-PCR)and protein(by flow cytometry) levels on K562R cell, whereas hOCT1 level measured by semi-quantity PCR showed lower expression in K562R cell lines than that of parental sensitive cell, indicating that low intracellular imatinib concentration may be due to lower affluence of imatinib by low level of hOCT1. (5) Real time PCR analysis showed no BCR-ABL/G6PD gene amplification and sequence analysis of the 374bp ABL kinase domain showed no mutation in K562R cell lines. Conclusion An imatinib resistance cell line K562R has been successfully established. Low expression of hOCT1 may be a key point mediating low intracellular imaitnib accumulation in K562R cell lines.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3527-3527
Author(s):  
Anne-Sophie Moreau ◽  
Xavier Leleu ◽  
Xiaoying Jia ◽  
Judith Runnels ◽  
Costas Pitsillides ◽  
...  

Abstract Background: Multiple Myeloma (MM) and Waldenstrom Macroglobulinemia (WM) are characterized by widespread involvement of the bone marrow (BM) as the result of successful homing, engraftment and growth of tumor cells at that site. The receptor for SDF-1, CXCR4 has already been implicated by us and others in the migration and homing of tumor cells to the bone marrow. Recently, a new receptor for the chemokine SDF-1 has been described, namely CXCR7. To date, it has been implicated in the migration of embryonic cells during neurogenesis in zebrafish. It has been reported to be expressed in cancer cells but its function remains unknown. We have previously shown that disruption of the CXCR4/SDF-1 axis interferes with homing of MM cells to the BM. To better understand the homing and migration of MM and WM tumor cells, we sought to study the expression and function of CXCR7. Methods: MM (U266, MM1.S, RPMI, OPM2, OPM1, KMS12BM) and WM (BCWM.1 and WSU-WM) cell lines were used. CD19+ and CD138+ cells were extracted from patient bone marrow samples by microbeads selection after informed consent. To determine the expression of CXCR7 on MM and WM cell lines as well as primary samples, we used flow cytometry and RT-PCR analysis. The migration of tumor cells towards SDF-1 was studied using the transwell boyden chamber migration assay. The adhesion of tumor cells to fibronectin using a fluorometric assay. The CXCR7 inhibitor CCX-754 (ChemoCentryx Inc., Mountain View, CA) was used. Results: CXCR7 was expressed in all cell lines tested except WSU-WM by flow cytometry and RT-PCR. Interestingly, U266 cell line did not express surface CXCR4 and expressed CXCR7 and therefore was used in further experiments to determine the differential role of CXCR7 in SDF-1 related function. Primary WM (n=14) and MM (n=7) cells expressed low intensity CXCR7 by flow cytometry. Use of the above cells in experiments utilizing small molecule antagonists of both CXCR4 and CXCR7 suggested that inhibiting the binding of SDF-1 to one receptor could impact the signaling functions of the other. Experiments are ongoing to clarify the nature of the interaction between these two SDF receptors. Furthermore, adhesion of U266 cells to fibronectin was increased in presence of SDF-1, and inhibited in the presence of CCX-7754. Further analysis to examine CXCR7 and CXCR4 antagonism in adhesion are ongoing. Conclusion: we showed for the first time CXCR7 expression on MM and WM tumor cells. Our results lead us to conclude that through binding of a shared ligand, CXCR7 and CXCR4 may modulate the biological activity of the other.


2008 ◽  
Vol 33 (4) ◽  
pp. 698-709 ◽  
Author(s):  
Yuqing Zhang ◽  
Min Li ◽  
Hao Wang ◽  
William E. Fisher ◽  
Peter H. Lin ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2341
Author(s):  
Normann Steiner ◽  
Karin Jöhrer ◽  
Selina Plewan ◽  
Andrea Brunner-Véber ◽  
Georg Göbel ◽  
...  

Therapy resistance remains a major challenge in the management of multiple myeloma (MM). We evaluated the expression of FLT3 tyrosine kinase receptor (FLT3, CD135) in myeloma cells as a possible clonal driver. FLT3 expression was analyzed in bone marrow biopsies of patients with monoclonal gammopathy of undetermined significance or smoldering myeloma (MGUS, SMM), newly diagnosed MM (NDMM), and relapsed/refractory MM (RRMM) by immunohistochemistry (IHC). FLT3 gene expression was analyzed by RNA sequencing (RNAseq) and real-time PCR (rt-PCR). Anti-myeloma activity of FLT3 inhibitors (midostaurin, gilteritinib) was tested in vitro on MM cell lines and primary MM cells by 3H-tymidine incorporation assays or flow cytometry. Semi-quantitative expression analysis applying a staining score (FLT3 expression IHC-score, FES, range 1–6) revealed that a high FES (>3) was associated with a significantly shorter progression-free survival (PFS) in NDMM and RRMM patients (p = 0.04). RNAseq and real-time PCR confirmed the expression of FLT3 in CD138-purified MM samples. The functional relevance of FLT3 expression was corroborated by demonstrating the in vitro anti-myeloma activity of FLT3 inhibitors on FLT3-positive MM cell lines and primary MM cells. FLT3 inhibitors might offer a new targeted therapy approach in a subgroup of MM patients displaying aberrant FLT3 signaling.


2004 ◽  
Vol 50 (2) ◽  
pp. 306-312 ◽  
Author(s):  
Stefan S Biel ◽  
Andreas Nitsche ◽  
Andreas Kurth ◽  
Wolfgang Siegert ◽  
Muhsin Özel ◽  
...  

Abstract Background: We studied electron microscopy (EM) as an appropriate test system for the detection of polyomavirus in urine samples from bone marrow transplant patients. Methods: We evaluated direct EM, ultracentrifugation (UC) before EM, and solid-phase immuno-EM (SPIEM). The diagnostic accuracy of EM was studied by comparison with a real-time PCR assay on 531 clinical samples. Results: The detection rate of EM was increased by UC and SPIEM. On 531 clinical urine samples, the diagnostic sensitivity of EM was 47% (70 of 149) with a specificity of 100%. We observed a linear relationship between viral genome concentration and the proportion of urine samples positive by EM, with a 50% probability for a positive EM result for urine samples with a polyomavirus concentration of 106 genome-equivalents (GE)/mL; the probability of a positive EM result was 0% for urine samples with <103 GE/mL and 100% for urine samples containing 109 GE/mL. Conclusions: UC/EM is rapid and highly specific for polyomavirus in urine. Unlike real-time PCR, EM has low sensitivity and cannot quantify the viral load.


Sign in / Sign up

Export Citation Format

Share Document